This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Think Integer (ITGR) Could Surge 29.03%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 29% in Integer (ITGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Integra Q1 Earnings Miss Estimates, Stock Down, '25 EPS Outlook Cut
by Zacks Equity Research
IART's first-quarter 2025 earnings lag the consensus mark. Q2 revenue projections are bleak.
Henry Schein Q1 Earnings Top Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
HSIC ends the first quarter of 2025 on a mixed note.
EXAS Stock Up on Q1 Earnings & Revenue Beat, 2025 Sales View Raised
by Zacks Equity Research
Exact Sciences ends the first quarter of 2025 on a solid note.
Hologic Q2 Earnings & Revenues Top, '25 EPS View Lowered, Stock Down
by Zacks Equity Research
HOLX delivers earnings and revenue beat in the second quarter of fiscal 2025 amid macroeconomic turbulence.
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts
by Zacks Equity Research
Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance.
OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands
by Zacks Equity Research
Despite strength in OPKO Health's revenues from the transfer of intellectual property, the company reports an overall soft first-quarter 2025 performance.
BD Stock Falls in Pre-Market Despite Q2 Earnings Beat, Margins Down
by Zacks Equity Research
BDX's overall topline in the second quarter of fiscal 2025 continues to benefit from strength in its Medical segment and geographic performances.
ICON's Q1 Earnings Surpass Estimates, Revenues Lag, Stock Down
by Zacks Equity Research
ICLR posts mixed results in the first quarter of 2025 due to ongoing clinical development and market volatility.
CVS Q1 Earnings & Revenues Beat, '25 EPS View Raised, Stock Up
by Zacks Equity Research
CVS Health delivers earnings and revenue beat in the first quarter of 2025.
Labcorp Q1 Earnings Surpass Estimates, Revenues Miss, Stock Gains
by Zacks Equity Research
LH delivers better-than-expected earnings in the first quarter of 2025.
Integer Holdings Q1 Earnings & Revenues Beat Estimates, Margins Expand
by Zacks Equity Research
ITGR tops first-quarter estimates with strong sales and EPS growth. Margins expand, driven by new products, acquisitions, and operational efficiency.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Integer (ITGR) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 3.15% and 1.29%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
What Analyst Projections for Key Metrics Reveal About Integer (ITGR) Q1 Earnings
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Integer (ITGR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Why Integer (ITGR) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Integer (ITGR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Integer (ITGR) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Strength Seen in Artivion (AORT): Can Its 7.9% Jump Turn into More Strength?
by Zacks Equity Research
Artivion (AORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Integer Holdings Stock in Your Portfolio
by Zacks Equity Research
ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.
Here's Why Integer (ITGR) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Integer (ITGR) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.